Christopher J. Senner has sold EXEL and made no open-market buys since Mar 2017

Christopher J. Senner is an accomplished finance executive serving as Executive Vice President and Chief Financial Officer (EVP, CFO) of Exelixis, Inc. (EXEL) since July 2015, where he oversees the global finance function, controllership, treasury, tax strategy, and financial planning to support the company's expansion in oncology therapeutics.( Under his leadership, Exelixis has transformed into a global, multi-product oncology company, facilitating commercial product launches and resource allocation for clinical development and drug discovery initiatives.(

Prior to Exelixis, Senner was Vice President of Corporate Finance at Gilead Sciences from 2010 to 2015, managing key financial operations including R&D and commercial planning.( He spent 18 years at Wyeth Pharmaceuticals (acquired by Pfizer), rising to CFO of the U.S. region in 2007 and leading divisional finance for pharmaceuticals and biopharma units.( Senner holds a B.S. in Finance from Bentley University and serves on the board of Quince Therapeutics.(

Written by Perplexity from public sources.